Cécile  Denis
  • E-mail :[email]
  • Phone : 01-49-59-56-05
  • Location : Le Kremlin-Bicêtre, France
Last update 2015-07-16 15:26:04.646

Cécile Denis PhD Haemostasis/Thrombosis

Course and current status

Cécile V. DENIS

Citizenship: French

Professional address: INSERM U. 1176, 80 rue du Général Leclerc, 94276 Le Kremlin-Bicêtre Cedex, tel: 33-1-49-59-56-05


Director INSERM Unit 1176 (40 people total)

Director of Research at INSERM (Institut National de la Santé et de la Recherche Médicale)



2006 Official habilitation to supervise PhD theses, University Paris 7

1993 PhD in Biological Sciences, University Paris 7

1989 Master in Biological Sciences University Paris 7, Major “Blood cells biology”

1987 Bachelor degree. Major: Cell Biology. University of Rennes I



Since 2015 INSERM U. 1176 HITh Hemostasis-Inflammation-Thrombosis

2006-2014 INSERM U. 770, “Hémostase et Dynamique Cellulaire Vasculaire”, Kremlin-Bicêtre Hospital

2001-2006 INSERM U. 143, “Hémostase et Biologie Vasculaire”, Kremlin-Bicêtre Hospital (Pr. Dominique Meyer). Research Officer 1st class INSERM. “Avenir 2001” program laureate INSERM

2000-2001 INSERM U. 143. Post-doctoral fellow.

1993-2000 Center for Blood Research, Harvard Medical School, Boston, USA (Pr. Denisa Wagner). Post-doctoral fellow

1988-1993 INSERM U143, “Hémostase et Thrombose”, Kremlin Bicêtre Hospital (Pr. Dominique Meyer and Dr. Dominique Baruch). PhD thesis. Grant recipient from the French Minister for Research and Technology



Chevalier Légion d’honneur 2012

Laureate Prize Bréant, Maujean et Albert 1er de Monaco 2007 of the French Academy of Sciences

Laureate Avenir program from INSERM for young scientists (2001)

Laureate young investigator award French Group for Thrombosis & Haemostasis (GEHT) (1993)



Author of 88 peer-reviewed publications, 1 book chapter and 85 abstracts presented in national and international meetings

6 granted patent applications, 1 under exclusibe licence.

22 conferences given at the invitation of organizing committees of national and international meetings



Member of Specialized Scientific Commission n°4 of INSERM (2012-2016)

Member of multinational PhD committees (Netherlands, Germany, Canada, France)

Member of evaluation committees for AERES (French evaluation body for research laboratories)

Member of evaluation committee for ANR (French funding agency)

Reviewer for scientific journals: Blood, Journal of Thrombosis and Haemostasis, PNAS, Arteriosclerosis Thrombosis and Vascular Biology, Plos Pathogens, Plos One, Thrombosis Research

Expertise activities for foreign funding agencies: FWO (Fonds Wetenschappelijk Onderzoek) in Belgium, NHLS (National Health Laboratory Service) Research Trust (South Africa), COFECUB (French-Brazilian projects), Italian Telethon (Italy) and the Landsteiner Foundation for Blood Transfusion (The Netherlands)

Member of the ethical committee CEEA26 for animal experimentation



Teaching participation: Paris 7 Master 2 CVHR “CardioVascular, Hemostasis, Respiration” and Master 1 module “Cell Biology, Microbiology and Therapeutic Innovations” Le Kremlin-Bicêtre Medical School.

Supervision of Master (5) and PhD theses (6)


Co-chairman of the Scientific and Standardization committee “Animal Models” of the International Society of Thrombosis & Haemostasis (ISTH)

Elected member of the board of the French Group for Thrombosis & Haemostasis (GEHT)

Member of the scientific council of AFH (Association Française des Hémophiles)

French Society of Hematology (SFH)




Scientific summary

My research focuses on the study of a number of hemostatic proteins: Von Willebrand factor (VWF), its cleaving protease ADAMTS13 and coagulation factors VIII (FVIII) and X (FX). These proteins are associated with hemorrhagic/thrombotic disorders: Von Willebrand disease (VWD), thrombotic thrombocytopenic purpura (TTP) and hemophilia. Particular axes of interests are:

1) Structure-function relationship of VWF and ADAMTS13 in vivo

VWF and ADAMTS13 variants are expressed in mice deficient in either VWF or ADAMTS13 by hydrodynamic injection, an in vivo transfection method. The activity of the variants is tested in a series of experiments aiming to study the hemorrhagic and thrombotic response of the mice. Mutations studies are chosen based on patients study performed in the framework of the VWD and TPP network coordinated by team members.

2) Clearance mechanisms of hemostatic proteins

We have recently identified hepatic and splenic macrophages as the cells responsible for VWF endocytosis. We are now lookinf for the recepor(s) involved in this process. FX clearance is also under study with a particukar focus on the role of the activation peptide.

3) VWF and Weibel-Palade bodies (WPBs) proteins

WPBs are endothelial storage granules the formation of which is driven by VWF. We have shown that VWF binds osteoprotegerin (OPG) a protein involved in bone metabolism and a resident of WPBs. We are presently looking for the physiological relevance if the VWF-OPG complex in plasma. 

Image d’exemple